Bone mineral density following long-term use of antiepileptic drugs in a tropical Asian country

Epileptic Disorders

Volumn 10, Issue 3, 2008, Pages 213-218

  Phabphal, Kanitpong ^a   Limapichat, Kitti ^a   Sathirapanya, Ponchi ^a   Setthawatcharawanich, Suwanna ^a   Leelawattana, Rattana ^a   Thammakumpee, Natawan ^a   Thamaprasit, Atchara ^a   Geater, Alan ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Antiepileptic drugs; Bone mineral density; Tropical Asian country

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; CLONAZEPAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PHOSPHATE; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ASIAN; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMALE; FEMUR NECK; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOPENIA; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; THAILAND; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTICONVULSANTS; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; BONE DENSITY; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX CHARACTERISTICS; THAILAND;

EID: 53349109891     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: 10.1684/epd.2008.0208     Document Type: Article

References (42)

1. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug induced bone loss in young male patients who have seizures. Arch Neurol 2002; 59: 781-6.
2. Berr JL, Mawer M, Walker DA. Effect of antiepileptic drug therapy and expose to sunlight on vitamin D status in institutionalized patients. In: Oxley J, ed. Chronic toxicity of antiepileptic drugs. New York: Raven Press, 1983: 185-91.
3. Boluk A, Guzelipek M, Savli H, et al. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004; 50: 93-7.
4. Brämswing S, Zittermann A, Berthod HK. Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adult. Calcif Tissue Int 2003; 73: 356.
5. Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. BMJ 1973; 4: 695-701.
6. Craven KL, Hawks SR. Cultural and western influences on the nutrition transition in Thailand. Promot Educ 2006; 13: 14-20.
7. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporptic Fractures Research Group. N Engl J Med 1995; 332: 767-73.
8. Ecevit C, Aydoǧan A, Kavakli T, et al. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 2004; 31: 279-82.
9. Elliott JO, Jacobson MP. Bone loss in epilepsy: barriers to prevention, diagnosis, and treatment. Epilepsy Behav 2006; 8: 169-75.
10. Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007; 16: 22-34.
11. Engel J Jr. International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42: 796-803.
12. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58: 1348-53.
13. Gilsanz V, Skaggs DL, Kovanlikaya A, et al. Differential effect of race on the axial and appendicular skeletons of children. J Clin Endocrinol Metab 1998; 83: 1420-7.
14. Hahn TJ, Hendin BA, Scharp CR, et al. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972; 287: 900-4.
15. Jaglal SB, Kreiger N, Darlington GA. Lifetime occupational physical activity and risk of hip fracture in woman. Ann Epidemiol 1995; 5: 321-4.
16. Kajadphai-Taungbodhitham A. Composition of ready cooked foods sampled in southern Thailand. Asia Pac J Clin Nutr 2007; 16(Suppl. 1): 52-7.
17. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. The Scientific Advisory Board and the Board of National Societies. Osteoporos Int 1996; 6: 256-61.
18. Kim SH, Lee JW, Choi KG, et al. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsia Behav 2007; 10: 291-5.
19. Kulak CA, Borba VZ, Bilezikian JP, et al. Bone mineral density and serum levels of 25-OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr 2004; 62: 940-8.
20. Kulak CA, Borba VZ, Silvado CE, et al. Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy. Arq Bras Endocrinol Metabol 2007; 51: 466-71.
21. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9.
22. Matsuda-Inuguchi N, Shimbo S, Zhang ZW, et al. Nutrient intake of working woman in Bangkok, Thailand, as studies by total food duplicate method. Eur J Clin Nutr 2000; 54: 187-94.
23. Mosekilde L, Christensen MS, Lund B, et al. The interrelationships between serum 25-hydroxycholcalciferol, serum parathyroid hormone and bone changes in anticonvulsant osteomalacia. Acta Endocrinol (Copenh) 1977; 84: 559-65.
24. Nelson DA, Simpson PM, Johnson CC, et al. The accumulation of whole body skeletal mass in third- and fourth-grade children: effects of age, gender, ethnicity, and body composition. Bone 1997; 20: 73-8.
25. Pack AM, Olarte LS, Morrell MJ, et al. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003; 4: 169-74.
26. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005; 57: 252-7.
27. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-Enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115: 177-86.
28. Petty SJ, Paton LM, O'Brien TJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology 2005; 65: 1358-63.
29. Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. BMJ 1970; 4: 73-6.
30. Sato Y, Kondo I, Ishida S. decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57: 445-9.
31. Sheth RD, Wesolowski CA, Jacop JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995; 127: 256-62.
32. Sheth RD. Bone health in epilepsy. Epilepsia 2002; 43: 1453-4.
33. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case controlled study. Seizure 1999; 8: 339-42.
34. Sukalakemala S, Brittin HC. Food practices, change, preferences, and acculturation of Thais in the United States. J Am Diet Assoc 2006; 106: 103-8.
35. Tekgul H, Serdaroglu G, Huseyinov A, et al. Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy. J Child Neurol 2006; 21: 411-4.
36. Tjellesen L, Christiansen C. Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants. Acta Neurol Scand 1982; 66: 335-41.
37. Tolman KG, Jubiz W, Sannella JJ, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975; 56: 45-50.
38. Verrotti A, Greco R, Morgese G, et al. Increased bone turnover in epileptic Patients treated with carbamazepine. Ann Neurol 2000; 47: 385-8.
39. Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002; 43: 1488-92.
40. Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999; 99: 269-75.
41. World Health Organization, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific Perspective: Redefining obesity and its treatment. Sydney: Health Communications, 2000.
42. Wang MC, Aguirre M, Bhudhikanok GS, et al. Bone mass and hip axis length in healthy Asian, black, Hispanic, and white American youths. J Bone Miner Res 1997; 12: 1922-35.